Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases

摘要: Current data on the concordance of KRAS, BRAF, PIK3CA mutation status or PTEN expression between primary tumors and metastases in colorectal cancer (CRC) are conflicting. We conducted a systematic review meta-analysis to examine discordance these four biomarkers corresponding CRC patients. The biomarker was used as reference standard. Concordance for were provided by 43, 16, 9 7 studies, respectively. pooled rate 92.0% (95% CI: 89.7%–93.9%) 96.8% 94.8%–98.0%) 93.9% 89.7%–96.5%) 71.7% 57.6%–82.5%) PTEN. false positive negative rates KRAS 9.0% 6.5%–12.4%) 11.3% 8.0%–15.8%), BRAF mutations highly concordant CRC, but loss is not. Nine percent patients with wild-type who received anti-EGFR treatment had mutant metastases, while metastases. These currently do not receive potentially beneficial treatment.